HOWL · Werewolf Therapeutics, Inc.

Werewolf Therapeutics’ Q1 2026 results reflect a deliberate operational pivot: R&D expenses fell 37% year-over-year to $8.2 million, driving net loss improvement from $18.1 million to $13.5 million despite a modest rise in G&A costs. This reduction aligns with the company’s strategic de-prioritization of JZP898 — now fully divested to Jazz Pharmaceuticals via an asset purchase agreement, terminating prior licensing terms and eliminating future investment in that IFNα program. Concurrently, Werewolf repaid all outstanding obligations under its May 2024 loan with K2 HealthVentures, removing debt service pressure and associated financial covenants. Though cash declined to $46.5 million as of March 31, 2026 — down $10.6 million from year-end — the company explicitly states it will update cash runway guidance “in the near future,” signaling active capital planning. Critically, management emphasizes ongoing evaluation of strategic alternatives for its core INDUKINE and INDUCER platforms, assisted by Piper Sandler, but provides no timeline or commitment to transaction outcomes. The forward-looking statements section underscores material uncertainty: the board has not approved any specific action, and the company disclaims obligation to update disclosures until a definitive decision is made. These developments collectively indicate a transition from broad platform advancement toward focused value optimization — a high-stakes inflection point for investors assessing viability, capital efficiency, and potential exit pathways.